The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Thrombin-activatable fibrinolysis inhibitor and the risk for recurrent venous thromboembolism
Abstract
The impact of fibrinolysis for predicting the risk for recurrent venous thromboembolism (VTE) is low. We prospectively followed up 600 patients with a first VTE and evaluated the thrombin-activatable fibrinolysis inhibitor (TAFI) as a risk factor for recurrence. A high TAFI level (75th or higher percentile in thrombosis patients) was associated with a 2-fold higher risk for recurrence compared with lower levels. The probability of recurrence 2 years after anticoagulation was 14.5% (95% confidence interval [CI], 8.6-20.4) among patients with high TAFI levels and 6.8% (95% CI, 4.3-9.3) among patients with lower levels (P = .006). Our data also support the concept of a linkage between fibrinolysis and the coagulation system. Patients with high TAFI levels had significantly higher levels of factors XI, VIII, and IX, and a high risk of recurrence was seen among patients with high TAFI levels and high levels of one of these factors. The relative risk (RR) for recurrence was highest among patients with high TAFI and high factor XI (RR, 2.9; 95% CI, 1.3-6.9), high factor VIII (RR, 6.5; 95% CI, 2.9-14.8), or high factor IX (RR, 2.0; 95% CI, 1.0-3.9) levels compared with patients with low levels of TAFI and one of these factors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
High plasma levels of factor VIII and the risk of recurrent venous thromboembolism
Kyrle, P. A., Minar, E., Hirschl, M., Bialonczyk, C., Stain, M., Schneider, B., Weltermann, A., Speiser, W., Lechner, K., & Eichinger, S. (2000) · New England Journal of Medicine · doi:10.1056/nejm200008173430702 · Cited by 763 · cited 1×
“Factor V Leiden, no. (%) 130 (29) 57 (37) .05 Prothrombin G20210A, no. (%) 34 ( 8 ) 15 (10) NS Factor VIII, IU/dL* 159 48 179 57 .0001 Factor IX, IU/dL* 123 25 130 28 .01 Factor XI, IU/dL* 102 23 107 23 .03”
Self-citationBaglin, T., Luddington, R., Brown, K., & Baglin, C. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14111-6 · Cited by 694
Cited by
Molecular mechanisms of fibrinolysis
Cesarman‐Maus, G., & Hajjar, K. A. (2005) · British Journal of Haematology · doi:10.1111/j.1365-2141.2005.05444.x · Cited by 748
Kyrle, P. A., & Eichinger, S. (2005) · The Lancet · doi:10.1016/s0140-6736(05)71880-8 · Cited by 616
Self-citationMeltzer, M. E., Lisman, T., de Groot, P. G., Meijers, J. C. M., le Cessie, S., Doggen, C. J. M., & Rosendaal, F. R. (2010) · Blood · doi:10.1182/blood-2010-02-267740 · Cited by 364
Risk assessment for recurrent venous thrombosis
Kyrle, P. A., Rosendaal, F. R., & Eichinger, S. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60962-2 · Cited by 261
Self-citationThrombophilia and Venous Thromboembolism: Implications for Testing
Cohn, D., Roshani, S., & Middeldorp, S. (2007) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-2007-985753 · Cited by 75
Metadata
- Authors
- Eichinger, S., Schönauer, V., Weltermann, A., Minar, E., Bialonczyk, C., Hirschl, M., Schneider, B., Quehenberger, P., & Kyrle, P. A.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2004-05-15
- Volume
- 103
- Issue
- 10
- Pages
- 3773-3776
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2079175463
- Cited by
- 160
- References
- 2
- FWCI
- 9.41
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Thrombin-activatable fibrinolysis inhibitor and the risk for recurrent venous thromboembolism. https://app.cochat.ai/papers/10.1182/blood-2003-10-3422
- The paper
- Eichinger, S., Schönauer, V., Weltermann, A., Minar, E., Bialonczyk, C., Hirschl, M., Schneider, B., Quehenberger, P., & Kyrle, P. A. (2004). Thrombin-activatable fibrinolysis inhibitor and the risk for recurrent venous thromboembolism. Blood. https://doi.org/10.1182/blood-2003-10-3422
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.